Risk of Outsourcing Provider Disruption or Contract Termination in Pharmaceutical Development

Risk that pharmaceutical development may be delayed or interrupted if contracts with external providers entrusted with clinical trials, manufacturing, preclinical studies or other activities end, or if operations are suspended due to natural disasters or failures involving equipment, infrastructure or other facilities.